NCT05589597

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

A Global Multicenter Phase 1/2 Trial of EO4010, a Novel Microbial Derived Peptide Therapeutic Vaccine, in Combination With Nivolumab and/or Bevacizumab, for Treatment of Patients With Previously Treated Metastatic Colorectal Carcinoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Enterome · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label multicenter study

Detailed description

This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	EO4010	Sequential assignment

Timeline

• Start date: 2023-06-01
• Primary completion: 2025-05-30
• Completion: 2025-05-30
• First posted: 2022-10-21
• Last updated: 2025-08-22

Locations

6 sites across 3 countries: United States, France, Spain

Regulatory

• FDA-regulated drug study